FINEARTS-HF trial reveals finerenone advantages for coronary heart failure with preserved ejection fraction

Finerenone diminished coronary heart failure (HF) occasions and cardiovascular loss of life in sufferers with HF and mildly diminished (HFmrEF) or preserved ejection fraction (HFpEF), in keeping with late-breaking analysis introduced in a Scorching Line session as we speak at ESC Congress 2024.

Explaining the rationale behind the trial, Principal Investigator, Professor Scott Solomon of the Brigham and Girls’s Hospital, Boston, USA, stated: “Sodium-glucose co-transporter 2 (SGLT2) inhibitors are the one therapy for HFmrEF/HFpEF with a powerful guideline advice and there stays a excessive unmet want for added therapies to enhance morbidity and mortality on this massive affected person inhabitants. Steroidal mineralocorticoid receptor antagonists (MRA) have confirmed advantages in HF with diminished ejection fraction (HFrEF), however their efficacy in HFmrEF/HFpEF has not been conclusively established. We investigated the non-steroidal MRA, finerenone, in sufferers with HFmrEF/HFpEF within the FINEARTS-HF trial, and a big constructive impression on outcomes was noticed.”

FINEARTS-HF was a double-blind, randomized trial in sufferers with HF (New York Coronary heart Affiliation [NYHA] useful class II-IV) and left ventricular ejection fraction (LVEF) of 40% or better. Extra inclusion standards included age 40 years or older, elevated natriuretic peptides and proof of structural coronary heart illness.

Eligible sufferers had been randomly assigned (1:1) to finerenone (as much as 40 mg as soon as each day relying on baseline estimated glomerular filtration fee [eGFR]) or placebo. The first endpoint was a composite of whole (first and repeat) worsening HF occasions and cardiovascular loss of life. Secondary endpoints included all-cause mortality and a composite kidney consequence (sustained 50% or better decline in eGFR, sustained decline in eGFR to lower than 15 ml/min/1.73 m2 or initiation of continual dialysis or kidney transplantation).

In whole, 6,001 sufferers had been randomized from greater than 650 websites throughout 37 nations. The imply age was 72 years and 46% had been girls. The imply LVEF was 53%, the bulk had NYHA class II HF (69%) and 20% of sufferers had been enrolled throughout or inside 7 days of a worsening HF occasion.

Over a median of 32 months, finerenone considerably diminished the first endpoint, with 1,083 occasions within the finerenone group and 1,283 occasions within the placebo group (fee ratio 0.84; 95% confidence interval [CI] 0.74-0.95; p=0.007). A major discount in whole worsening HF occasions was noticed with finerenone in contrast with placebo (842 vs. 1,024 occasions; fee ratio 0.82; 95% CI 0.71-0.94; p=0.006). Cardiovascular loss of life was non-significantly diminished within the finerenone arm (8.1% and eight.7%; hazard ratio [HR] 0.93; 95% CI 0.78-1.11). The first consequence outcomes had been constant in all prespecified subgroups, together with these based mostly on ejection fraction or baseline use of SGLT2 inhibitors.

There was no distinction within the finerenone and placebo teams for all-cause mortality (16.4% and 17.4%, respectively; HR 0.93; 95% CI 0.83-1.06) or the composite kidney consequence (2.5% and 1.8%, respectively; HR 1.33; 95% CI 0.94-1.89).

Critical opposed occasions had been related between the teams (finerenone: 38.7%; placebo: 40.5%). Finerenone elevated the danger of investigator-reported hyperkalemia (9.7% vs. 4.2%) however lowered the danger of hypokalaemia (4.4% vs. 9.7%).

The FINEARTS-HF trial gives the primary particular proof that an MRA is useful in HFmrEF/HFpEF. We’ve got 4 pillars of guideline-directed medical remedy in HFrEF however solely SGLT2 inhibitors as a therapy choice for HFmrEF/HFpEF. Provided that finerenone was useful in sufferers already receiving an SGLT2 inhibitor, our findings level to finerenone as a brand new second pillar in HFmrEF/HFpEF.”

Professor Scott Solomon, Brigham and Girls’s Hospital, Boston, USA